Výsledky vyhledávání - "Iii Ha Burris"

P3-16-01: Safety Profile and Clinical Activity of Single-Agent BKM120, a Pan-Class I PI3K Inhibitor, for the Treatment of Patients with Metastatic Breast Carcinoma

Autor: David Demanse, B Graña-Suárez, N. F. Homji, J. Baselga, S Hirawat, Johanna C. Bendell, Iii Ha Burris, Lucia Trandafir, Jordi Rodon, Cornelia Quadt, L.L. Siu, Razak Ar Abdul, E. di Tomaso, Cristian Massacesi

Publikováno v: Cancer Research. 71:P3-16

Background Phosphatidylinositol 3-kinase (PI3K) is critical to cancer cell growth, survival, and metabolism. BKM120 is an oral pan-class I (α, β, γ, δ) PI3K inhibitor that has demonstrated in vitro and in vivo tumor cell growth inhibition in a ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85543a1671d1c3bc86984df849b1e87f
https://doi.org/10.1158/0008-5472.sabcs11-p3-16-01

Zobrazit plný text záznamu

P5-13-09: Correlation of Oncotype DX Recurrence Scores with Pathologic Response Following Neoadjuvant Ixabepilone and Cyclophosphamide in Patients with HER2−Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial

Autor: Iii Ha Burris, D. A. Yardley, Sy Huh, S. L. Ketchum, N. W. Peacock, C Hendricks, C. Chao, John D. Hainsworth, C. Yoshizawa

Publikováno v: Cancer Research. 71:P5-13

Background: Ixabepilone (Ixa) is active in anthracycline and taxane-refractory metastatic breast cancer as well as in the neoadjuvant setting where Ixa yielded a pathologic complete response (pCR) rate of 11%. In this study, we evaluated Ixa in combi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16c80a51a9d4501c1d6b7d1b97cdb4c5
https://doi.org/10.1158/0008-5472.sabcs11-p5-13-09

Zobrazit plný text záznamu

OT2-01-03: Eribulin in Women with Locally Advanced Breast Cancer Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy: A Sarah Cannon Research Institute Phase II Trial

Autor: John D. Hainsworth, N. W. Peacock, Iii Ha Burris, D. A. Yardley

Publikováno v: Cancer Research. 71:OT2-01

Background: Little evidence currently exists to support the use of further therapy for women with localized breast cancer who do not achieve pathologic complete response (pCR) after treatment with standard neoadjuvant chemotherapy. Eribulin is a nove

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ace7a52dd776906f1f91538c2e9cd591
https://doi.org/10.1158/0008-5472.sabcs11-ot2-01-03

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání